Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

View Full Paper
Ask AI
Bookmark
Share

Authors

MKManali KamdarSSScott R. SolomonPJPatrick Johnston

Discussion

Loading...

Member takes

Overview

Long-term follow-up reveals robust progression-free survival and manageable safety profile for liso-cel in relapsed or refractory large B-cell lymphoma patients.

Key Points

  • Liso-cel demonstrated long-term clinical benefit with high rates of progression-free survival in large B-cell lymphoma patients, suggesting its effectiveness.
  • Over 40 months of cumulative follow-up, median overall survival and progression-free survival rates were not reached in the liso-cel group.
  • The autologous CAR T cell therapy showed no new safety signals or significant adverse events over the follow-up.
  • Results from the LTFU study further imply liso-cel’s potential as a curative second-line treatment for relapsed or refractory large B-cell lymphoma.

Cite This Study

Kamdar et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df32https://doi.org/10.1182/blood-2025-3710
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL2025 · 2 citations
  2. 2Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study2025 · 1 citations
  3. 3Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry2025
  4. 4Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study2026 · 1 citations
  5. 5Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies2025 · 1 citations